Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.

The Japanese group licenses sapablursen from Ionis for $280m.

Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.

The companies press on with vilastobart and IMPT-314... up to a point.

The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.

J&J decides not to opt in to erzotabart, and Genmab pulls the plug.

The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.

Could a new ADC project distract attention away from evorpacept?

A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.

Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.